Morphimmune
MorphImmune is a biotech company that Philip Low previously co-founded.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
Umoja Biopharma raises $53M Series A to develop in vivo CAR T-cell immunotherapies for adult and pediatric tumors
Seattle-based Umoja Biopharma raised $53 million in a Series A to advance its preclinical in vivo CAR T-cell immunotherapy platform for blood and organ tumors in adult and pediatric patients, aiming to generate cancer-fighting cells inside the body. The company was founded last year by CEO Andy Scharenberg and collaborators from Seattle Children’s Research Institute and Purdue University, with MPM Capital and Qiming Venture Partners USA leading the round.
